Richard Kender
Directeur/Membre du Conseil chez BICYCLE THERAPEUTICS PLC
Fortune : 352 920 $ au 31/05/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Eric Shaff | M | 48 | 10 ans | |
Pierre Legault | M | 63 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 5 ans |
Kevin Lee | M | 55 |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009.
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | 9 ans |
Janice Bourque | F | 67 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 8 ans |
Mohammed Khoso Baluch | M | 66 | 12 ans | |
Veronica Jordan | M | 73 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK.
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 5 ans |
Marcus Chapman | M | 53 | 9 ans | |
Gregory Winter | M | 73 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | 15 ans |
Thomas Kuhn | M | 50 | 15 ans | |
Kate Bingham | F | 58 |
BicycleTx Ltd.
BicycleTx Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2017, part of Bicycle Therapeutics Plc, BicycleTx Ltd. provides business support services. The company is based in Babraham, UK. | 8 ans |
Michael Skynner | M | 55 |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | 8 ans |
Joshua Hare | M | 61 | 10 ans | |
Mohamed Wa’el Ahmed Hashad | M | 61 | 3 ans | |
Pascale Fouqueray-Grellier | M | 61 | 15 ans | |
Stephen Berenson | M | 63 | 5 ans | |
Sebastien Bolze | M | - | 15 ans | |
Alistair Milnes | M | 51 | 3 ans | |
Carlo Tanzi | M | - | 9 ans | |
Dalton Smart | M | 58 | 15 ans | |
David Ege | M | 50 | 21 ans | |
Stephen Sands | M | 67 | - | |
Paul Lehr | M | 56 | 8 ans | |
Chirfi Guindo | M | 58 | 13 ans | |
Ursula Ungaro | F | 73 | 3 ans | |
Neil Hare | M | 54 | 9 ans | |
Jennifer Russo Wortman | F | - | 9 ans | |
Matthew Henn | M | 49 | 12 ans | |
Tom Glocer | M | 63 | 17 ans | |
Willard Dere | M | 70 | 7 ans | |
Caroline Litchfield | F | 55 | 34 ans | |
Patricia Russo | F | 71 | 29 ans | |
Dennis Ausiello | M | 78 | 9 ans | |
Thomas DesRosier | M | 69 | 8 ans | |
Jose-Carlos Gutiérrez-Ramos | M | 61 | 3 ans | |
Claire Fraser-Liggett | M | 68 | 1 ans | |
Gary O'Neill | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 11 ans |
Kurt Graves | M | 56 | 9 ans | |
Travis Thompson | M | - | 6 ans | |
Paul Biondi | M | 54 | 4 ans | |
Douglas Losordo | M | 65 | 3 ans | |
Lisa Locklear | F | 64 | 1 ans | |
Pascale Boissel | F | 57 | 9 ans | |
Sophie Hallakou-Bozec | M | - | 15 ans | |
Allan Gabor | M | - | 11 ans | |
James Sutcliffe | M | 68 | 1 ans | |
Sylvie Bertrand | F | - | 3 ans | |
Naveed Iqbal Siddiqi | M | - |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 3 ans |
Nigel Crockett | M | 59 | 5 ans | |
Chan Beals | M | - |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 8 ans |
Pamela Eisele | F | - | 15 ans | |
Kelly M. Brady | F | - | 6 ans | |
Quentin Durand | M | - | 5 ans | |
Barbara McGovern | M | - | 9 ans | |
Lisa von Moltke | M | 65 | 4 ans | |
Teresa Young | M | 57 | 4 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Robert P. Luciano | M | - | 23 ans | |
Kenneth Frazier | M | 69 | 30 ans | |
Richard Kogan | M | 81 | 21 ans | |
Roger Pomerantz | M | 67 | 9 ans | |
P. Vagelos | M | 94 | 19 ans | |
John G. Aunins | M | 63 | 31 ans | |
Raymond Gilmartin | M | 82 | 2 ans | |
Richard Clark | M | 77 | 6 ans | |
James Corbett | M | 65 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | 4 ans |
Myrtle Potter | F | 65 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support.
FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. Medical SpecialtiesHealth Technology FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices for the treatment of peripheral artery disease. The company's products include Rinspirator, Seath, and SilverHawk plaque excision system. Its products are used for disposable catheter system that removes plaque and reopens blocked arteries. The company was founded by John B. Simpson in October 1996 and is headquartered in Redwood City, CA. | 18 ans |
Lee Kalowski | M | 43 | 6 ans | |
David Berry | M | 47 | 5 ans | |
Noubar Afeyan | M | 60 | 10 ans | |
Fred Hassan | M | 78 | 6 ans | |
David Norton | M | 72 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 2 ans |
Robert Palmisano | M | 79 |
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | 2 ans |
David Arkowitz | M | 62 | 7 ans | |
David Burgstahler | M | 55 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 7 ans |
Meryl Zausner | F | 67 | 5 ans | |
Lorence Kim | M | 49 | 6 ans | |
Craig Thompson | M | 71 | 10 ans | |
Grégory Behar | M | 55 | 9 ans | |
Thomas C. Südhof | M | 68 |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | 1 ans |
Linda Harty | F | 63 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
Matthew Monaghan | M | 56 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
Kevin J. Horgan | M | 64 | 8 ans | |
Julie Gerberding | M | 69 | - | |
Joseph Romanelli | M | 50 | 19 ans | |
Werner Cautreels | M | 71 | 3 ans | |
Charles Harwood | M | 70 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 6 ans |
William Klitgaard | M | 71 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
Thomas Robert Cech | M | 76 | - | |
Rochelle Lazarus | F | 76 | 16 ans | |
Donald S. Brooks | M | 88 | - | |
Ken Meyers | M | 62 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | - |
Steven Goldstone | M | 78 | 6 ans | |
William Harrison | M | 80 | - | |
Wendell Weeks | M | 64 | 16 ans | |
Duncan MacDonald | M | 56 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | 6 ans |
Duke Rohlen | M | 56 |
FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. Medical SpecialtiesHealth Technology FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices for the treatment of peripheral artery disease. The company's products include Rinspirator, Seath, and SilverHawk plaque excision system. Its products are used for disposable catheter system that removes plaque and reopens blocked arteries. The company was founded by John B. Simpson in October 1996 and is headquartered in Redwood City, CA. | 3 ans |
Jeffrey B. Child | M | 64 |
FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. Medical SpecialtiesHealth Technology FoxHollow Technologies, Inc. designs, develops, manufactures, and sells medical devices for the treatment of peripheral artery disease. The company's products include Rinspirator, Seath, and SilverHawk plaque excision system. Its products are used for disposable catheter system that removes plaque and reopens blocked arteries. The company was founded by John B. Simpson in October 1996 and is headquartered in Redwood City, CA.
ev3, Inc.
ev3, Inc. Medical SpecialtiesHealth Technology ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support. | 5 ans |
Richard Henriques | M | 68 | 27 ans | |
Caroline Dorsa | F | 64 | 22 ans | |
Carlos Eduardo Represas de Almeida | M | 78 | - | |
Kumi Sato | F | - | 6 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 82 | 82,00% |
Royaume-Uni | 15 | 15,00% |
France | 11 | 11,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Richard Kender
- Réseau Personnel